Johnson & Johnson has unveiled a comprehensive $5.5 billion settlement proposal designed to bring closure to decades of litigation alleging that the company’s talc-based products caused ovarian cancer in thousands of women. The healthcare conglomerate’s latest offer represents a significant increase from previous settlement attempts and could potentially resolve approximately 60,000 pending lawsuits against the multinational corporation.
The New Jersey-based pharmaceutical and consumer products manufacturer, which maintains operations in Ireland through multiple facilities including a substantial presence in Cork and Limerick, has faced mounting legal pressure over allegations that its talcum powder products contained asbestos and caused cancer. Despite the proposed settlement, Johnson & Johnson continues to maintain that its talc products are safe and do not contain asbestos or cause cancer.
This latest settlement framework would be distributed over a 25-year period, providing compensation to claimants who assert they developed ovarian cancer or mesothelioma following prolonged use of the company’s talc-based products, including its iconic baby powder. The proposal requires approval from 75 percent of current claimants to proceed through a bankruptcy process involving a subsidiary entity specifically created to manage these liabilities.
The pharmaceutical giant initially discontinued sales of talc-based baby powder in North America in 2020, transitioning to cornstarch-based formulations instead. This decision came after years of declining sales and increasing litigation costs, though the company emphasized the change was purely a commercial decision rather than an admission of product safety concerns. Two years later, in 2022, Johnson & Johnson announced it would cease global sales of talc-based baby powder entirely.
Johnson & Johnson’s operations in Ireland represent a significant component of the company’s European manufacturing and research infrastructure. The company employs thousands of workers across Irish facilities that produce various pharmaceutical and medical device products for global distribution. Ireland’s role as a European headquarters for numerous multinational pharmaceutical companies, supported by initiatives from the IDA Ireland, has made the country a crucial hub for the sector’s research, development, and manufacturing activities.
This settlement proposal marks the third attempt by Johnson & Johnson to resolve the talc litigation through bankruptcy proceedings. Previous efforts to limit liability through subsidiary bankruptcy filings were rejected by federal courts, which determined the parent company possessed sufficient financial resources to address claims without resorting to bankruptcy protection. Legal experts following the case suggest this substantially larger offer may have better prospects for acceptance given the increased compensation pool and refined legal strategy.
The talc litigation has proven extraordinarily costly for Johnson & Johnson beyond direct settlement payments. The company has spent billions on legal defence costs, experienced reputational damage, and faced significant investor scrutiny regarding its litigation strategy and product safety protocols. Several juries have awarded substantial verdicts against the company, though many have been reduced or overturned on appeal.
Claimants’ attorneys have expressed mixed reactions to the latest settlement proposal. While some acknowledge the increased financial commitment represents meaningful compensation for affected individuals, others argue the 25-year payment timeline and bankruptcy mechanism remain problematic. Critics contend that elderly claimants, many suffering from terminal illnesses, deserve more immediate compensation rather than extended payment schedules.
The proposed settlement structure would establish a trust fund managed through bankruptcy proceedings, a mechanism that has been employed in other mass tort litigation cases involving asbestos and other hazardous substances. This approach potentially provides Johnson & Johnson with greater finality and prevents future talc-related claims from emerging after the settlement receives court approval.
Financial analysts monitoring the situation suggest the $5.5 billion commitment, while substantial, remains manageable for Johnson & Johnson given its strong balance sheet and diversified revenue streams across pharmaceutical, medical device, and consumer health segments. The company’s recent strategic restructuring, including the separation of its consumer health division into a standalone entity named Kenvue, may have influenced the timing and structure of this settlement proposal.
The ultimate resolution of this litigation carries implications beyond Johnson & Johnson, potentially establishing precedents for how multinational corporations address legacy product liability claims through bankruptcy mechanisms while maintaining ongoing operations. Legal observers anticipate intense negotiations between company representatives and claimants’ counsel before any final agreement receives necessary approvals from both claimants and the bankruptcy court overseeing proceedings.